Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy

Diabetes Care

Volumn 21, Issue 12, 1998, Pages 2135-2139

  Imano, Eiichi ^a   Kanda, Tsutomu ^a   Nakatani, Yoshihisa ^a   Nishida, Tsutomu ^a   Arai, Katsuml ^a   Motomura, Masaaki ^a   Kajimoto, Yoshitaka ^b   Yamasaki, Yoshimitsu ^b   Hori, Masatsugu ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; METFORMIN; TROGLITAZONE;

ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE;

EID: 0031768586     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.12.2135     Document Type: Article

References (20)

1. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
2. Alzaid AA: Microalbuminuria in patients with NIDDM: an overview. Diabetes Care 19:79-89, 1996
3. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995
4. Mogensen CE, Keane WF, Bennet PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viverti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
5. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of Steno studies. Diabetologia 34:164-170, 1991
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 28:103-117, 1995
7. Marre M, Leblanc H, Suarez L, Guyenne T-T, Menard J, Passa P: Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 294:1448-1452, 1987
8. Suter SL, Nolan JJ, Wallance P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
9. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, The Troglitazone Study Group: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46:433-439, 1997
10. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
11. Defronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
12. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
13. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone. J Clin Invest 96:354-360, 1995
14. Law RE, Meehan WP, Xi X-P Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
15. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendation to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 25:107-112, 1995
16. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 20:516-519, 1997
17. Hanley AJG, Harris SB, Barnie A: Usefulness of bioelectrical impedance analysis in a population-based study of diabetes among native Canadians (Abstract). Im J Obes 18:O383, 1994
18. Decken T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T: Microalbuminuria: implications' for micro- and macrovascular disease. Diabetes Care 15:1181-1191, 1992
19. Bailey CJ, Path MRC, Turner RC: Drug therapy: metformin. N Engl J Med 334:574-579, 1996
20. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K, Kondo M: Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 46:981-983, 1997